Cardiac contractility modulation for the treatment of moderate to severe HF.

This article will discuss the science behind CCM therapy, the presumed mechanisms of action, the pre-clinical studies that shaped subsequent endeavors, and the clinical trials that support its use. Expert opinion: The introduction of CCM therapy bridges a therapeutic gap for patients with few or no other therapeutic options for NYHA III heart failure. PMID: 33287592 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33287592?dopt=Abstract

Source: Expert Review of Medical Devices - December 9, 2020 Category: Medical Devices Tags: Expert Rev Med Devices Source Type: research